Comparison of 4F-PCC in obese and nonobese patients with life-threatening bleeding or requiring emergent surgery.

ABSTRACT:

Background

Four-factor prothrombin complex concentrate (4F-PCC) dosing is based on INR and actual body weight (ABW), with maximum doses not to exceed the dose used in patients weighing >100 kg (Kcentra PI). There are limited data comparing the efficacy of 4F-PCC between patients with low body weight ≤100 kg (LoWT) and high body weight >100 kg (HiWT).

Methods

We conducted a retrospective cohort study of patients on warfarin who received 4F-PCC for life-threatening major bleeding or requiring emergent surgery between January 2015 to June 2018 at three academic medical centers. These data were combined with a dataset from 2 randomized Phase 3b clinical trials.

Results

We included 388 patients who received 4F-PCC, 318 (82%) were LoWT, and 70 (18%) were HiWT. Indication fo

SUBMITTER: Rimsans J 

PROVIDER: S-EPMC8626605 | biostudies-literature | 2021 Dec

REPOSITORIES: biostudies-literature